# Flonoltinib

Source: https://onco.cc/drugs/flonoltinib/  
OnCo record `flonoltinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Flonoltinib is an oral kinase inhibitor from Chengdu Zenitar Biomedical Technology Co., Ltd, in registered phase 2 trials for myeloproliferative neoplasms.

## Summary

Flonoltinib is listed on ClinicalTrials.gov as an intervention in 3 registered phase 2 trials sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd, in myeloproliferative neoplasms. A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral kinase inhibitor
- Mechanism: A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below.

## Sources

- ClinicalTrials.gov: trials of Flonoltinib: https://clinicaltrials.gov/search?intr=Flonoltinib

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- trials: [Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera](https://onco.cc/trials/nct07232290/)

---
JSON: https://onco.cc/api/v1/entities/flonoltinib.json